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Abstract
Single-gene analyses indicate that maternal genes associated with metabolic conditions (e.g., 
obesity) may influence the risk of neural tube defects (NTDs). However, to our knowledge, there 
have been no assessments of maternal-fetal metabolic gene-gene interactions and NTDs. We 
investigated 23 single nucleotide polymorphisms among 7 maternal metabolic genes (ADRB3, 
ENPP1, FTO, LEP, PPARG, PPARGC1A, and TCF7L2) and 2 fetal metabolic genes (SLC2A2 and 
UCP2). Samples were obtained from 737 NTD case-parent triads included in the National Birth 
Defects Prevention Study for birth years 1999–2007. We used a 2-step approach to evaluate 
maternal-fetal gene-gene interactions. First, a case-only approach was applied to screen all 
potential maternal and fetal interactions (n=76), as this design provides greater power in the 
assessment of gene-gene interactions compared to other approaches. Specifically, ordinal logistic 
regression was used to calculate the odds ratio (OR) and 95% confidence interval (CI) for each 
maternal-fetal gene-gene interaction, assuming a log-additive model of inheritance. Due to the 
number of comparisons, we calculated a corrected p-value (q-value) using the false discovery rate. 
Second, we confirmed all statistically significant interactions (q<0.05) using a log-linear approach 
among case-parent triads. In step 1, there were 5 maternal-fetal gene-gene interactions with 
q<0.05. The “top hit” was an interaction between maternal ENPP1 rs1044498 and fetal SLC2A2 
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rs6785233 (interaction OR=3.65, 95% CI: 2.32–5.74, p=2.09×10−8, q=0.001), which was 
confirmed in step 2 (p=0.00004). Our findings suggest that maternal metabolic genes associated 
with hyperglycemia and insulin resistance and fetal metabolic genes involved in glucose 
homeostasis may interact to increase the risk of NTDs.
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1. INTRODUCTION
Neural tube defects (NTDs) are among the most common, costly, and deadly of all human 
congenital anomalies whose etiologies remain largely unknown [1, 2]. Maternal pre-
gestational diabetes and pre-pregnancy obesity are two well-established risk factors for 
NTDs [3–19]. While the exact mechanisms behind these associations are unknown, it is 
believed that glucose homeostasis plays an important role. At the time of neural tube closure 
(approximately the fourth week of gestation), mothers with poorly regulated glucose levels 
are likely to have an altered intrauterine environment leading to abnormal organogenesis. 
Several genes related to glucose homeostasis have been previously identified in human and 
animal studies. Furthermore, genes related to glucose homeostasis have been associated with 
type 2 diabetes and obesity risk in genome-wide association studies (GWAS) [20–23]. Work 
from our group indicated an association between inherited (i.e., fetal) variation in the UCP2 
gene and NTDs [24]. SLC2A2 is an important glucose transporter during embryonic neural 
tube development [25]. Additionally, we found associations between maternal genotypes in 
FTO, TCF7L2, and LEP and NTDs suggesting maternal genetic effects may cause changes 
in intrauterine environment and play a role in disease risk [24]. The Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) study has demonstrated that common genetic variants 
in genes such as TCF7L2 are associated with fasting and post-challenge glucose levels 
during pregnancy [26]. Because of these findings, we sought to evaluate the interactions 
between maternal and fetal genes related to glucose homeostasis and the risk of NTDs.
2. MATERIALS AND METHODS
2.1 Subjects
The study population included NTD case-parent triads (n=737) from the National Birth 
Defects Prevention Study (NBDPS), with estimated dates of delivery between January 1, 
1999 and December 31, 2007. Details of the NBDPS have been published elsewhere [27]. In 
brief, the NBDPS is a population-based case-control study of major structural birth defects. 
For the period 1999–2007, case infants with one or more congenital anomalies were 
ascertained through ten birth defects surveillance systems throughout the United States 
(Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North 
Carolina, Texas, and Utah) and included live births, stillbirths, and induced pregnancy 
terminations. NTDs included in the NBDPS had British Pediatric Association (BPA) codes 
for the diagnoses anencephaly (740.0), craniorachischisis (740.1), spina bifida (741.0), and 
encephalocele (742.0). Abstracted data for all NTD case infants were reviewed by clinical 
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geneticists using specific criteria, including standardized case definitions and confirmatory 
diagnostic procedures [28]. Infants/fetuses with known single gene disorders or 
chromosomal abnormalities were excluded from the NBDPS. Mothers completed a one-hour 
computer assisted telephone interview (CATI) in English or Spanish between 6 weeks and 2 
years after the estimated date of delivery. The interview included sections on maternal 
conditions and illnesses, lifestyle and behavioral factors, and multivitamin use.
2.2 Maternal and Fetal Candidate Genes and Single Nucleotide Polymorphisms (SNPs)
The selection criterion for candidate genes and SNPs were reported previously [24]. Briefly, 
genes and SNPs selected were those identified as being associated with type 2 diabetes or 
obesity in multiple GWAS studies, or those with supporting evidence from both candidate 
gene studies and animal models. Maternal candidate genes included in the current study 
were ADRB3, ENPP1, FTO, LEP, PPARG, PPARGC1A, and TCF7L2. Fetal candidate 
genes analyzed were UCP2 and SLC2A2 [20, 25, 29–34]. Information on the SNPs 
evaluated and the selection criteria used is listed in Table 1.
2.3 DNA Samples and Genotyping Analysis
Buccal brushes from mothers, fathers, and infants were collected as part of the NBDPS [35]. 
DNA was extracted from buccal cells and a standard quality control procedure was applied 
to each sample before they were submitted to the NBDPS sample repository [35]. To assure 
genotyping proficiency, high quality, and high concordance among all NBDPS laboratories, 
annual evaluations are conducted to confirm the performance of each laboratory (See 
Supplemental Material). Our laboratory at the University of Texas at Austin, Dell Pediatric 
Research Institute has passed all of these evaluations with a score of 100%. SNPs were 
assayed using TaqMan method (Life Technologies Corporation, Carlsbad, CA) and 
genotypes were read and discriminated on the ABI PRISM® 7900HT Sequence Detection 
System (Life Technologies Corporation, Carlsbad, CA).
2.4 Statistical Analysis
The characteristics of cases and case mothers were summarized using counts and 
proportions for the following variables: phenotype (spina bifida, anencephaly, 
encephalocele); infant sex (male, female); maternal age (<20, 20–34, ≥35 years); maternal 
race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, other); maternal 
education (<12, 12, 13–15, >15 years); maternal folic acid supplementation during three 
months before conception through the first month of pregnancy (no, yes); maternal pre-
pregnancy body mass index or BMI (underweight [<18.5 kg/m2], average weight [18.5–24.9 
kg/m2], overweight [25.0–29.9 kg/m2], and obese [≥30.0 kg/m2]; and maternal pre-
pregnancy diabetes (no, yes). For each analyzed polymorphism, samples for which a 
genotype could not be assigned and triads that had genotype combinations that were 
inconsistent with Mendelian inheritance were determined. For each subject, the number of 
genotyping failures (i.e., genotypes that could not be assigned) was determined. These 
analyses were performed using Intercooled Stata, version 12.1 (StataCorp LP, College 
Station, TX).
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We utilized a 2-step approach to evaluate maternal-fetal gene-gene interactions [36]. For 
step 1, a case-only approach was used to screen all potential interactions (n=76), as this 
design provides greater power in the assessment of gene-gene interactions compared to a 
case-control design or case-parent triads [37]. The case-only design has been described 
elsewhere [38] and has been used extensively for the assessment of gene-environment and 
gene-gene interactions [36, 38–43]. Specifically, ordinal logistic regression was used to 
calculate the odds ratio (OR) and 95% confidence interval (CI) for each maternal-fetal gene-
gene interaction, assuming a log-additive model of inheritance. The genotypes for each SNP 
were classified according to the number of minor alleles present (i.e., 0, 1, 2). In the ordinal 
logistic regression model, the maternal genotype was treated as the dependent variable and 
the fetal genotype was treated as the independent variable [36, 37, 43]. Due to the number of 
comparisons, we calculated a corrected p-value (q-value) to control for the false discovery 
rate (FDR) at 0.05 [44, 45]. These analyses were conducted using Intercooled Stata version 
12.1 (StataCorp LP, College Station, TX). All interactions where q<0.05 were included in 
step 2.
For step 2 (i.e., case-parent triad approach), maternal-fetal gene-gene interactions that were 
associated with NTDs in the case-only analyses (i.e., q<0.05) were investigated using log-
linear models for joint effects [46]. To test the no-interaction null hypothesis, we calculated 
a 2-degrees-of-freedom likelihood ratio test (LRT) statistic as twice the difference of the log 
likelihoods for the log-linear model that included two parameters indexing the inherited 
genotype (SNP1), two parameters indexing the maternal genotype (SNP1), and two 
interaction terms representing the product of maternal-fetal SNP1-SNP2 pairwise genotypes 
(SNP2 being the fetal “interacting” SNP) and a reduced model that excluded the interaction 
terms [36, 46]. These analyses were run using LEM [47], a program for log-linear analysis 
with missing data that allows information from case-parent triads that have not been 
completely genotyped (e.g., father not available) to be included in the analysis for any given 
variant [48]. To reduce concerns regarding possible mating stratification bias [49, 50], we 
also examined interactions among case-parent triads in which both parents were reported to 
be non-Hispanic White. Additionally, analyses were conducted in three subgroups: 1) those 
case-parent triads with spina bifida only (to reduce the potential for phenotypic 
heterogeneity); 2) those case-parent triads where mothers did not have pre-gestational 
diabetes (in order to determine if these effects were independent; and 3) those case-parent 
triads where mothers were not obese (in order to determine if these effects were independent 
of obesity).
3. RESULTS
Participation in the NBDPS for the period 1999–2007 was 74% among NTD case mothers, 
yielding 1,553 families available for analysis. Among those, 759 (49%) provided buccal 
brushes (1,787 individuals). Genotyping was performed on DNA samples derived from 
these 759 families. Based on quality control checks, 18 families (2% of families) were 
excluded for being inconsistent with Mendelian inheritance at more than two genotypes. 
Additionally, 47 subjects were excluded for failure at more than 11 genotypes (>50%), 
leaving a total of 737 case-parent triads (97% of the original sample). Of those, 317 were 
complete triads, 313 were dyads, and 107 were monads with only one person in the family. 
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After these quality control measures were applied, at least 95% of the samples for each 
variant were available; therefore the genotypes were considered of sufficiently high quality 
for analysis.
The distributions of key characteristics among NTD case-parent triads are presented in 
Table 2. Spina bifida was the most common phenotype among case subjects (n=449, 
60.9%). Furthermore, a majority of case mothers were non-Hispanic White (n=439, 59.8%). 
Among case mothers, 176 were obese (25.4%), 13 had pre-pregnancy diabetes (1.8%), and 
28 had gestational diabetes (4.2%). The only characteristics presented in Table 2 that were 
significantly different between interviewed case mothers who provided buccal brushes and 
those who did not were race/ethnicity (those who provided buccal brushes were more likely 
to be non-Hispanic White compared to those who did not) and education (those who 
provided buccal brushes were more likely to have >12 years education compared to those 
who did not), data not shown.
Of the 76 interactions evaluated, five had q<0.05 (Table 3). Among these five, four were 
confirmed using log-linear models among case-parent triads (step 2). Our results were 
similar when restricted to non-Hispanic white mating combinations (data not shown). 
Specifically, the following interactions were confirmed: maternal ENPP1 rs1044498-fetal 
SLC2A2 rs6785233 (interaction OR=3.65, 95% CI: 2.32–5.74, q=0.001, LRT p=0.00004); 
maternal LEP rs12706831-fetal SLC2A2 rs6785233 (interaction OR=0.45, 95% CI: 0.29–
0.71, q=0.016, LRT p=0.00001); maternal ENPP1 rs1044498-fetal SLC2A2 rs5400 
(interaction OR=1.98, 95% CI: 1.34–2.92, q=0.016, LRT p=0.001); and maternal LEP 
rs2071045-fetal SLC2A2 rs5400 (interaction OR=0.50, 95% CI: 0.32–0.77, q=0.03, LRT 
p=0.008). As in our previous assessment [24], our results were similar when our analyses 
were restricted to 1) those case-parent triads with spina bifida only; 2) those case-parent 
triads where mothers did not have pre-gestational diabetes; and 3) those case-parent triads 
where mothers were not obese (Table 4 for results among non-obese mothers) [24].
4. DISCUSSION
To our knowledge, this is the first study reporting maternal-fetal gene-gene interactions in 
metabolic genes and their associations with NTD risk. Significant interactions were 
identified between the fetal SLC2A2 gene and maternal variants in LEP and ENPP1 genes. 
Specifically, four of the 76 interactions were q<0.05 and were confirmed in step 2 of our 
analysis. The minor alleles of maternal ENPP1 and fetal SLC2A2 were associated with 
increased risk of NTDs, whereas the minor alleles of LEP and fetal SLC2A2 were inversely 
associated with NTD risk. The direction of these associations is consistent with our previous 
single locus analysis [24]. Interestingly the maternal (ENPP1 rs1044498, LEP rs12706831, 
and LEP rs2071045) and fetal (SLC2A2 rs6785233 and SLC2A2 rs5400) SNPs identified as 
being significant in these analyses were not significant in single locus analyses [24], 
suggesting the importance of evaluating factors that may not have significant “main” effects. 
It is noteworthy and SLC2A2 gene is known to contribute to impaired glucose tolerance and 
type 2 diabetes [51]; however, we have previously evaluated potential maternal effect of 
SLC2A2 SNPs and no significant association was observed [24].
Lupo et al. Page 5













Leptin is a hormone produced and secreted by white adipose tissue and has profound effects 
on eating behavior, metabolic rate, endocrine function, and glucose homeostasis. Leptin 
deficiency in both mice and humans causes morbid obesity and diabetes, and replacement 
treatment leads to decreased food intake, normalized glucose homeostasis, and increased 
energy expenditure [32, 52–55]. Two genetic markers adjacent to human LEP gene have 
been found to be modestly associated with NTDs possibly via an inherited effect, 
irrespective of maternal BMI [56]. In our previous study, we observed a modest increase of 
NTD risk (though not statistically significant) among women who carried the minor allele of 
SNP rs2071045 [24]; however, the functionality of this SNP is unknown.
Ectonucleotide pyrophosphate phosphodiesterase (ENPP1) is a membrane-bound 
glycoprotein that inhibits insulin receptor signaling. ENPP1 is the same protein as liver 
nucleotide phosphodiesterase and liver alkaline phosphodiesterase 1 and a member of a 
family of five enzymes (ENPP1–5) that regulate nucleotide metabolism [57]. The K121Q 
polymorphism (rs1044498) in exon 4 of ENPP1 gene has been associated with insulin 
resistance in some populations [31] but not others [58–60]. There is evidence suggesting that 
this variant interacts with adiposity in modulating glucose homeostasis [61, 62]; however, 
the possible effect of this variant on obesity remains unclear, with variable results [62–64]. 
We did not find a significant association between the ENPP1 gene and NTD risk when 
evaluating main genetic effects in our previous assessment [24].
At the time of neural tube closure (approximately the 4th week of gestation), an embryo 
receiving excessive amounts of glucose may not be able to regulate these levels, which 
subsequently leads to abnormal organogenesis and birth defects [25, 65, 66]. In mice, Glut2 
is expressed from the 8-cell stage onward [67]. Under the condition of maternal 
hyperglycemia, inactivation of the Glut2 gene in mouse can protect embryos from maternal 
diabetes-induced NTDs [25]. Our previous study shows that fetal variants in SLC2A2 (the 
human homolog of mouse Glut2) alone does not significantly influence NTD risk [24]. 
However, in this analysis, it appears as though SLC2A2 may interact with maternal LEP and 
ENPP1 genes to modify the risk of NTDs, suggesting SLC2A2 may confer sensitivity of the 
developing embryos under compromised intrauterine environment.
An important strength of our study is the use of data from the NBDPS, the largest 
population-based study of birth defects, which provided a unique opportunity to examine the 
interactions between maternal and fetal genes on NTD risk. The case-parent triad design is 
immune to population stratification bias in the assessment of fetal genotypes [50]. The log-
linear modeling approach to analyses also allowed us to include data from incomplete triads 
(i.e., genotype data is missing for one or two individuals) [48, 68]. An additional strength of 
the NBDPS is the extensive and standardized case review employed by clinical geneticists, 
which maximizes homogeneity among case groups. The main weakness of this study was 
the limited proportion of families with biologic samples (49%), which may limit the 
generalizability of our findings. In addition, clinical data such as insulin resistance or fasting 
blood glucose levels are not available as part of the NBDPS; therefore it is not possible to 
exclude mechanisms other than their associations with maternal obesity or impaired glucose 
homeostasis that alter the intrauterine environment. In conclusion, our findings suggest that 
maternal metabolic genes associated with hyperglycemia and insulin resistance and fetal 
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metabolic genes involved in glucose homeostasis may interact to increase the risk of NTDs. 
Replication of these findings in other populations and investigation of additional genes is 
warranted. Furthermore, since maternal obesity and diabetes are also risk factors for other 
malformations [5, 8, 69], assessing the maternal-fetal gene-gene interactions in other birth 
defects will broaden our understanding of diabetes and obesity-related teratogenicity.
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• Single-gene analyses indicate that maternal genes associated with metabolic 
conditions may influence the risk of neural tube defects (NTDs)
• In order to evaluate the interactions between maternal and fetal genes related to 
glucose homeostasis and the risk of NTDs we investigated 23 single nucleotide 
polymorphisms among 7 maternal metabolic genes and 2 fetal metabolic genes
• Samples were obtained from 737 NTD case-parent triads included in the 
National Birth Defects Prevention Study
• We found 5 statistically significant maternal-fetal gene-gene interactions
• Our findings suggest that maternal metabolic genes associated with 
hyperglycemia and insulin resistance and fetal metabolic genes involved in 
glucose homeostasis may interact to increase the risk of NTDs
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Table 2




 Spina bifida 449 60.9
 Anencephaly 217 29.4
 Encephalocele 71 9.6
Infant sex
 Male 337 47.9
 Female 366 52.1
Maternal age
 <20 83 11.3
 20–34 556 75.4
 ≥35 98 13.3
Race/ethnicity
 Non-Hispanic White 439 59.8
 Non-Hispanic Black 34 4.6
 Hispanic 221 30.1
 Other 40 5.5
Education (years)
 <12 142 19.3
 12 184 25.0
 13–15 226 30.7
 >15 185 25.0
Folic acid supplementationa
 No 351 47.6
 Yes 386 52.4
Body mass index (kg/m2)
 Underweight (<18.5) 28 4.1
 Normal (18.5–24.9) 336 48.6
 Overweight (25.0–29.9) 152 21.9
 Obese (≥30) 176 25.4
Pre-pregnancy diabetes
 No 724 98.2
 Yes 13 1.8
Gestational diabetes
 No 667 95.8
 Yes 29 4.2
a
Three months before conception through the first month of pregnancy
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Table 4
Top maternal-fetal metabolic gene-gene interactions in non-obese mothers associated with neural tube defects, 
National Birth Defects Prevention Study, 1999–2007
Maternal SNP Fetal SNP Interaction ORa 95% CIb p-value
ENPP1 rs1044498 SLC2A2 rs6785233 3.24 1.83–5.74 5.18E-05
LEP rs12706831 SLC2A2 rs6785233 0.54 0.31–0.93 0.0027
ENPP1 rs1044498 SLC2A2 rs5400 1.78 1.12–2.86 0.0153
LEP rs2071045 SLC2A2 rs5400 0.58 0.37–0.91 0.0259
LEP rs2071045 SLC2A2rs6785233 0.49 0.27–0.88 0.0172
LEP rs12706831 SLC2A2 rs5400 0.58 0.37–0.91 0.0176
LEP rs11760956 SLC2A2 rs6785233 0.85 0.50–1.44 0.5506
LEP rs3828942 SLC2A2 rs6785233 0.72 0.43–1.25 0.2552
a
Interaction odds ratio (OR) from case-only analysis
b
Confidence interval (CI)
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